Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp

Bullboard Posts

Post by jwalliscaon Oct 07, 2020 11:54pm

175 Views

Post# 31684903

Interpreting Virtual Mesa News 10 & 24 September

Well, what to say... As said in my Daily Wrap, a friend gave me a heads-up that how I interpreted the two releases (10 & 24 Sep) may not have been accurate. I present below how he believes they should be interpreted. If that turns out to be the case, my apologies for being too passionate about what the wording said.

Sernova News 24-9-2020 - Link

LONDON, ONTARIO - TheNewswire - September 24, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, announced today that Dr. Philip Toleikis, President and CEO, will provide a corporate update as part of the Company Presentations at the upcoming BIO Investor Forum Digital international biotech investor conference from October 13-15, 2000. Dr. Toleikis will also be engaged with the BIO One-on-One Partnering meetings.

"Amidst the COVID-19 pandemic, we are leveraging the proliferation of the virtual conference format. This virtual conference will enable us to increase the awareness level amongst an expanded base of potential investors and partnering prospects about Sernova's significant advancements, including first-time diabetes clinical trial findings, a technology acquisition for our cell therapy therapeutics platform, and local immune protection technology licensing and research collaboration arrangements. The BIO One-on-One Partnering meeting sessions will also enable us to continue discussions and further evaluate opportunities," said Dr. Philip Toleikis, President and CEO of Sernova.

Sernova's presentation will be available on-demand to attendees of the BIO Investor Forum Digital conference. For more details on Sernova's presentation, please visit https://www.bio.org/events/bio-investor-forum-digital/company-presentations .

Sernova News 19-9-2020 - Link

London, Ontario - TheNewswire - September 10, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, announced today that Dr. Philip Toleikis, President and CEO, will be a member of the Cell and Gene Therapies for Chronic Conditions panel at the virtual 2020 Cell & Gene Meeting on the Mesa. The panel session will be available on-demand to attendees as of Thursday, October 15, 2020. Dr. Toleikis will also provide an update on Sernova's clinical and research programs as part of the 2020 Company Presentations segment of the conference.

The panel will discuss the latest developments in Cell and Gene therapies for chronic conditions and will be moderated by Paul Laikind, Ph.D., President, and CEO of ViaCyte, Inc. In addition to Drs. Toleikis and Laikind, panelists are Pavan Cheruvu, M.D., CEO, Axovant Gene Therapies; Jane Lebkowski, Ph.D., President of R&D, Regenerative Patch Technologies, Inc.; and Emile Nuwaysir, Ph.D., President and CEO, BlueRock Therapeutics.

The panel will also participate in one of only two daily Live Streaming Sessions with Questions and Answers from participants on October 13, 2020 from 12:00 - 1:00pm PST.

Sernova's Corporate Update presentation will be available on-demand to attendees of the Virtual Cell & Gene Meeting on the Mesa throughout the conference. For more details on the panel and Sernova's presentation, please visit www.meetingonthemesa.com.

I have interpreted the wording very bullishly and posted that we should, hopefully, expect something akin to the best thing since sliced bread. My friend said not so fast jwall.

Firstly, Virtual Mesa is more a business type gathering rather than scientific. As such, he said lots of juicy details may not happen.

Secondly, he noted the wording implies within those at virtual Mesa rather than the general public. He also noted that there is no guarantee that any of the information at Virtual Mesa would be later in the public domain. That said, there is an implication that at least some of it might be.

He also suggested that there may be news issued because of how Virtual Mesa information is being handled. Because Sernova tends to not hype anything it releases, he concludes that even though we are likely to get something, but maybe not how I interpreted what we should expect.